Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF

A Phase 2 Randomized, Double-Masked, Study to Evaluate the Safety and Preliminary Efficacy of ATG003 in Patients With Neovascular Age-Related Macular Degeneration (NV-AMD) Receiving Frequent Maintenance Intravitreal Anti-VEGF Antibody Therapy (Ranibizumab or Bevacizumab)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00607750

Enrollment

Registered

2008-02-06

Start date

2008-05-31

Completion date

2010-05-31

Last updated

2010-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Related Macular Degeneration

Keywords

Wet AMD, Comentis, ATG003, mecamylamine

Brief summary

This study is a double-masked, randomized, placebo-controlled study of the safety and preliminary efficacy of ATG003 (topical mecamylamine) in patients receiving maintenance injections of either ranibizumab or bevacizumab. Study Hypothesis: Mecamylamine could be effective in the treatment of neovascular AMD.

Interventions

DRUGATG003 (mecamylamine)

1% Ophthalmic solution, eyedrop BID, 48 weeks

DRUGPlacebo

Placebo eyedrops, BID, 48 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

56 Years to No maximum

Healthy volunteers

Inclusion criteria

* \> 55 years of age * clinical diagnosis of neovascular AMD

Exclusion criteria

* confounding ocular condition

Design outcomes

Primary

Measure	Time frame
To evaluate the safety of ATG003 (mecamylamine HCL ophthalmic solution)	Day 1 - Week 50

Secondary

Measure	Time frame
To evaluate the efficacy of ATG003	Day 1 - Week 50

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026